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Abstract
Background: The human neurotropic virus, JC virus (JCV), is the etiologic agent of the fatal demyelinating disease of the
central nervous system, Progressive Multifocal Leukoencephlopathy (PML) that is seen primarily in immunodeficient
individuals. Productive infection of JCV occurs only in glial cells, and this restriction is, to a great extent, due to the activation
of the viral promoter that has cell type-specific characteristics. Earlier studies led to the hypothesis that glial-specific
activation of the JCV promoter is mediated through positive and negative transcription factors that control reactivation of
the JCV genome under normal physiological conditions and suppress its activation in non-glial cells.
Methodololgy/Principal Findings: Using a variety of virological and molecular biological approaches, we demonstrate that
the alternative splicing factor SF2/ASF has the capacity to exert a negative effect on transcription of the JCV promoter in
glial cells through direct association with a specific DNA sequence within the viral enhancer/promoter region. Our results
show that down-regulation of SF2/ASF in fetal and adult glial cells increases the level of JCV gene expression and its
replication indicating that negative regulation of the JCV promoter by SF2/ASF may control reactivation of JCV replication in
brain.
Conclusions/Significance: Our results establish a new regulatory role for SF2/ASF in controlling gene expression at the
transcriptional level.
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Introduction
JCV is a human polyomavirus that infects greater than 80% of
the human population during childhood [1], [2]. Replication of
the neurotropic strain of JCV in glial cells causes the fatal
demyelinating disease of the central nervous system, progressive
multifocal leukoencephalopathy (PML), which is seen in patients
with underlying immunocompromised conditions, notably among
AIDS patients [3], [4], [5], [6]. Recently, several cases of PML
have been reported in patients under treatment with immuno-
modulatory drugs including Natalizumab, Rituximab, and Efali-
zumab, indicating that alterations in immune status may lead to
reactivation of latent and/or passing virus in human brain [7], [8],
[9], [10]. Like other polyomaviruses, the JCV genome is composed
of double-stranded circular DNA of approximately 5 kb in size
with a bi-directional non-coding control region that is located
between the early and late coding sequences. The early coding
region is responsible for expression of large T-antigen, small t-
antigen, and a group of T’ proteins, all of which are produced
upon alternative splicing of a specific primary transcript [11].
Similarly, alternative splicing of the late transcript results in
production of the viral capsid proteins VP1, VP2, and VP3 all of
which are important for completion of the viral lytic cycle and
formation of viral particles. Processing of both early and late
primary transcripts requires participation of splicing factors
including SF2/ASF, an ubiquitous factor which plays a pivotal
role in alternative and constitutive splicing of precursor mRNAs of
mammalian cells [12], [13], [14], [15], [16]. Of particular interest,
the notion that SF2/ASF was first discovered as a cell type-specific
regulator of another well-studied member of the polyomavirus
family, SV40, based on its ability to modulate splicing of the viral
early gene, thus effecting the expression of large T-antigen and
small t-antigen expression at the post transcriptional level [17],
[18]. The non-coding control region of the neurotropic strain of
JCV, Mad-1, is composed of two 98 bp tandem repeats that have
cell type-specific characteristics and its activation primarily occurs
in glial cells such as oligodendrocytes and astrocytes [3], [4].
Earlier results from our laboratory and others led to the
identification of several constitutive and inducible cellular factors
with the ability to positively and negatively control JCV gene
transcription [19], [20]. These observations led us to postulate that
transcription of the JCV promoter is controlled by a group of
transcription factors that universally silence expression of the viral
genome under normal conditions and the level of their expression
and/or activities are changed under certain physiological
conditions such as immunosuppression, thus providing an
opportunity for the virus to replicate in the permissive cells of
the CNS. Here, we examined the possible effect of SF2/ASF on
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e14630the regulation of JCV gene expression and viral replication in glial
cells. Our results show that while SF2/ASF plays a role, similar to
that seen in SV40, in splicing viral transcripts, it has a profound
impact on transcription of the viral genome and replication of JCV
in glial cells. Our results show that overexpression of SF2/ASF
suppresses JCV gene transcription in human glial cells. Accord-
ingly, suppression of SF2/ASF enhances the level of viral
replication in astrocytic cells. These observations provide the first
evidence for regulation of a promoter activity by the splicing
factor, SF2/ASF, and shed new light onto regulation of JCV gene
transcription and replication.
Results
SF2/ASF suppresses replication of JCV in glial cells
To investigate the effect of SF2/ASF on replication of JCV,
primary human fetal astrocytes, PHFA, were transfected with JCV
Mad-1 DNA, either alone or together with a plasmid expressing
SF2/ASF in sense or antisense orientation. Overexpression of
SF2/ASF had a negative effect on replication of JCV DNA
(Fig. 1A) and production of the viral proteins, VP1 and
agnoprotein (Fig. 1B). In the antisense orientation, expression of
SF2/ASF showed no inhibitory effect, suggesting that the
overexpression of SF2/ASF, as shown in Fig. 1E, is required for
the observed suppression. Expression of SF2/ASF in PHFA also
decreased the copy number of the virus during the course of
infection, indicating that the decrease in viral gene expression by
SF2/ASF has an impact on the viral lytic cycle and its propagation
(Fig. 1C). In cells expressing SF2/ASF in the antisense orientation,
more virus was detected in the culture media. Examination of viral
transcripts by RT-PCR further established the inhibitory effect of
SF2/ASF on expression of the JCV early and late genome
(Fig. 1D).
Effect of SF2/ASF on splicing of the JCV transcript
To further demonstrate the effect of SF2/ASF on splicing of the
JCV transcript, a plasmid containing the JCV early promoter
expressing the early transcripts was introduced into PHFA along
Figure 1. Overexpression of SF2 inhibits JCV propagation in PHFA cells. A. Southern blot analyses of JCV-infected PHFA cells. In lane 1, 2 ng
of lineralized Mad-1 genome was used as positive control. In lane 2, DNA samples from uninfected cells were loaded as negative control. B. Western
blot analyzes of whole cell extracts prepared in parallel to DNA samples in panel A, using specific antibodies against VP1 and agnoprotein. In lane 1,
whole cell extracts from uninfected cells was loaded as negative control. Western blot analyzes of same extracts with anti-Grb2 antibody was used as
loading control. C. Q-PCR analyses of the viral particles in the JCV infected-cells culture medium. D. RT-PCR analyses of JCV early (T-Ag) and late (VP1)
gene products in JCV infected PHFA cells. In lane 1, Kb ladder was loaded as molecular weight marker. In lane 2, JCV Mad-1 genome was used as a
positive control. E. Western blot analyzes of endogenous (SF2/ASF) and overexpressed (T7-SF2/ASF) levels of SF2/ASF in PHFA cells. Grb2 was probed
in the same membranes as loading control.
doi:10.1371/journal.pone.0014630.g001
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vector (pCGT7). RNA analysis was carried out by RT-PCR using
primers that amplify alternatively spliced forms of JCV early
transcripts (Fig. 2A). Interestingly, results showed that ectopic
expression of SF2/ASF significantly diminished the level of the
viral transcript, suggesting that SF2/ASF may have a negative
effect on transcription of the JCV promoter (Fig. 2B). To further
investigate the specificity of this observation, PHFA were
transfected with a plasmid containing the CMV promoter
expressing the JCV early transcript. As shown in Fig. 2C,
expression of SF2/ASF had no effect on transcription of the
CMV promoter expressing and that JCV early RNA was
synthesized and in cells with overexpression of SF2, unspliced
viral RNAs were accumulated and splicing of the primary
transcripts for production of small t-antigen RNA was severely
suppressed. These observations suggest that similar to its effect on
splicing of SV40 [18], overexpressed SF2/ASF can also impair
JCV early RNA splicing.
The unanticipated observation of the suppression of JCV
promoter activity by SF2/ASF in transfected cells prompted us to
determine whether transcription of the integrated copy of the JCV
genome in cellular chromosomes can be influenced by SF2/ASF.
To this end, we utilized a transgenic mouse cell line containing the
JCV early promoter expressing the early genome. Results from
RNA analysis by RT-PCR showed that ectopic expression of SF2/
ASF severely suppresses production of JCV RNA but not control
GAPDH transcripts (Fig. 2D). Examination of early gene
expression at the protein level corroborated results from RNA
analysis showing that production of SF2/ASF inhibits accumula-
tion of the viral early protein, T-antigen, in the cells (Fig. 2E).
Again, this observation was specific to JCV gene expression as
evaluation of SV40 early protein production in SVGA, which
contains an integrated copy of the SV40 early region, showed no
effect of SF2/ASF on SV40 T-antigen expression (Fig. 2F).
Inhibition of JCV promoter activity by SF2/ASF
In the next series of experiments we measured the effect of SF2/
ASF on transcription of JCV early and late promoters. Results from
a series of co-transfection experiments showed that overexpression
of SF2/ASF in glial cells suppresses the activities of both the JCV
early and late promoters (Fig. 3A), whereas inhibition of SF2/ASF
abrogates JCV promoter activity inhibition by SF2/ASF (Fig. 3B).
Thespecificityofthisobservationwastestedwith transcriptionassay
using E2F-1, and BKV promoter sequences. Notably, under similar
conditions, ectopic expression of SF2/ASF exhibited no inhibitory
impact on the transcription of E2F-1, and BKV-early and –late
promoter activities (Fig. S1), pointing the specificity of our
observation on JCV gene transcription.
To better understand the events associated with SF2/ASF
suppression of JCV promoter activity, we designed a series of
experiments to assess the ability of SF2/ASF to bind to the JCV
promoter sequence. ChIP analysis of BSB8 cells demonstrated
association of SF2/ASF with the JCV regulatory region. The
DNA corresponding to the 98 bp tandem sequence of the JCV
promoter was immunoprecipitated with antibody that pulled down
SF2/ASF, suggesting the association of SF2/ASF with JCV DNA
in BSB8 cells (Fig. 4A). To more precisely identify the region
within the viral promoter that is a binding site for SF2/ASF, we
used a series of oligonucleotides, named CR1, CR2, CR3, and
CR4, (Fig. 4B), as probes in gel shift assays. To avoid any problems
associated with non-specific binding, we used highly purified
bacterially produced SF2/ASF in the binding reaction. As shown
in Fig. 4B only CR3, which corresponds to the central region of
the 98 bp repeat, showed binding activity to SF2/ASF. Further-
more, results from the supershift studies pointed to association of
GST-SF2/ASF with the CR3 domain of JCV promoter (Fig.4C).
Next, we performed a series of gel shift experiments using
nuclear extracts from PHFA and CR3 DNA probe to assess SF2/
ASF interaction with the JCV DNA sequence. Results from gel
shift experiments showed the detection of a major DNA-protein
complex whose formation was disturbed by unlabeled CR3 DNA
competitor but not by CR2 under similar conditions, pointing to
the specificity of the DNA-protein complex (Fig. 5A). The addition
of RNase to the binding reaction enhanced the CR3-protein
complex, suggesting that removal of the RNA molecules in the
extract facilitates the interaction of CR3 binding protein to the
CR3 DNA probe. This is an interesting observation as SF2/ASF is
a known RNA binding protein. To investigate the identity of the
protein associated with CR3, a CR3-associated complex in PHFA
was fractionated on a preparative native polyacrylamide gel
(Fig. 5C) and the complex was analyzed by SDS-PAGE followed
by Western blot using anti-SF2/ASF antibody. As seen in Fig. 5D,
a sample corresponding to the CR3 nucleoprotein complex named
GP2 reacted with anti-SF2/ASF antibody, indicative of SF2/ASF
association with CR3 nucleoprotein complex.
RRM1 domain of SF2/ASF interacts with the JCV
promoter DNA sequence and inhibits viral gene
transcription
SF2/ASF has a modular structure consisting of two copies of the
N-terminus RNA recognition motif, RRM1 and RRM2, followed
by an arginine-serine rich, RS, domain in its C-terminus [16],
[21], (Fig. 6A). To assess the importance of these domains in the
control of JCV gene transcription, we created a series of deletion
mutants of SF2/ASF and examined their expression in PHFA
(Fig. 6A and B). The association of each mutant protein with the
JCV promoter was investigated by ChIP assay and the results
showed that mutant protein with no RRM1 showed no binding
activity to JCV DNA. On the other hand, mutant protein
containing only RRM1 exhibited strong binding activity to the
JCV promoter (Fig. 6C). Results from transcription experiments
showed that expression of RRM1 in PHFA is sufficient for
suppression of the JCV promoter by SF2/ASF protein (Fig. 6D).
Previous studies have indicated that SF2/ASF mainly localizes
to the nucleus in various cell types and it shuttles between the
nucleus and cytoplasm [16], [21], [22]. In accordance with this
observation, analyses of the sub-cellular localization of SF2/ASF
in PHFA cultures by immunocytochemistry also showed nuclear
localization with speckled appearance (Fig. 6E). Interestingly, the
SF2-Mut-RRM1 construct, which retains RRM2 and RS
domains, was localized in both of the cellular compartments,
nucleus and cytoplasm. On the other hand, the RRM1 domain
alone was exclusively localized to the nucleus in PHFA cells.
Suppression of SF2/ASF promotes JCV replication in
astrocytes
Examination of SF2/ASF levels in primary fetal and adult
astrocytes showed lower levels of this protein in fetal astrocytes
compared to those in adult astrocytes, which had more than a
three-fold higher level (Fig. 7A). This was an interesting
observation as earlier results from our lab showed poor infection
by JCV of adult astrocytes compared to fetal astrocytes. To
investigate the involvement of SF2/ASF on JCV replication in
these cells, we down-regulated expression of SF2/ASF with a
lentivirus encoding shRNA that specifically targets SF2/ASF
expression (Fig. S4) and demonstrated that the introduction of
lenti-SF2/ASF shRNA but not the control lentivirus in the JCV
SF2 Inhibits JCV Transcription
PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e14630Figure 2. Effect of SF2/ASF on JCV early gene splicing in glial cells. A. Schematic structure of JCV early region unspliced and spliced RNAs
and, the size of the expected amplification products with a primer set (PF and PR), used for the amplification of JCV gene products in panels B, C, and
D. B. SF2/ASF inhibits expression of JCV early region driven by its own promoter. pBlueScript KS JCV early reporting JCV early region under JCV
promoter (pBlue-JCV.E), was transiently transfected into PHFA cells in the presence or absence of an SF2/ASF expression plasmid. Total RNA was
extracted and used for cDNA synthesis by reverse transcriptase reaction. JCV-early region gene products (pre-mRNA, t-Ag and T-Ag) were amplified
and separated on a 3% agarose gel and stained with ethidium bromide. Lane 2 was pBlue-JCV.E plasmid DNA amplified as positive control. Lane 3
was untransfected PHFA cell extracts used as a negative control. All the bands reflecting the amplification products were separately cut from the gels,
purified and RNA identities were confirmed by sequencing. GAPDH was also amplified in the same cDNA samples as input control. C. SF2/ASF inhibits
splicing of JCV early region driven by CMV promoter. PHFA cells were transiently-transfected with pCMV-JCV.E in the presence or absence of an SF2/
ASF expression plasmid. Total RNA was extracted and processed for reverse transcriptase reaction as described in panel B. In lane 2, pCMV-JCV.Early
plasmid DNA was amplified and loaded as a positive control of primary transcript. Lane 3 was un-transfected PHFA cell extracts and was used as
negative control of amplification. D. BSB8 cells were transfected with either vector alone (lane 3) or with SF2/ASF (lane 4) expression plasmids.
Expression of JCV-Early gene products were analyzed by RT-PCR as described in panels B and C. U-87 MG cells (lane 2) were also processed as lanes 3
and 4, and were used as negative control of amplification. E. Over-expression of SF2/ASF inhibits T-Ag expression in BSB8 cells. BSB8 cells were plated
in 6-well dishes and transfected with SF2/ASF expression plasmid in increasing concentrations (1X and 3X). Whole cell extracts were prepared at 2nd
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astrocytes (Fig. 7B). Results from Western blot analysis verified an
increased level of viral capsid protein production, VP1, in cells
with a decreased level of SF2/ASF (Fig. 7C). Further, results from
immunocytochemical staining of the infected cells showed 53%
and 136% increase in the number of VP1 positive cells in fetal and
adult infected astrocytes, respectively. Of note, lenti-SF2/ASF
shRNA was able to suppress 64% and 72% of SF2/ASF
expression in adult and fetal astrocytes, respectively (shown in
Fig. 7C). Thus, it is evident that a modest decrease in the level of
SF2/ASF can augment the level of JCV replication in the
permissive cells. In addition, immunohistological evaluation of
brain sections from PML patients showed a marked decrease in
the level of SF2/ASF expression when compared to normal brain
sections (Fig. S2).
Discussion
It is believed that JCV may enter many cell types, yet only
under certain immunosuppressive conditions does it enter into a
lytic infection cycle in glial cells. Earlier studies established that cell
type-specific reactivation of JCV in glial cells is primarily regulated
at the transcriptional level [19], [20]. In this respect, several
transcription factors including YB-1, Pura, GF-1, Egr-1, c-jun,
NF1, and others were identified based on their ability to modulate
JCV promoter activities in glial cells. Of note, none of these
regulators were restricted to glial cells, and their overexpression, in
most areas, failed to stimulate transcription of JCV in non-glial
cells, suggesting that the JCV promoter in general is under a
negative regulation in non-permissive cells. Accordingly, one may
speculate on the involvement of inducible glial specific activator
which becomes reactivated and promotes JCV gene transcription
and replication during the course of immunosuppression. Thus, it
is conceivable that the combination of ubiquitous negative and
inducible positive glial specific factors determines the level of viral
gene expression in glial and non-glial cells. Here, we identified an
RNA splicing regulatory protein, SF2/ASF, which is ubiquitously
expressed in all cell types as a negative regulator of JCV gene
transcription. This is not a universal event for the other members
of the polyomavirus family including SV40 and BKV and requires
a specific DNA sequence located within the 98 bp tandem
promoter region. Our results demonstrate that a decrease in the
level of SF2/ASF increases the level of viral gene expression and
replication in glial cells and has no positive impact on JCV
expression in non-glial cells (Fig. S3), suggesting that a positive
glial-specific activator is required to initiate viral gene expression.
SF2/ASF also suppresses expression of the JCV promoter in
transformed cells whose viral genome is integrated in host
chromosomes. Our DNA binding experiments identified a CR3
region of the JCV 98 bp repeat that is conserved in PML (Mad)
and non-PML (archetype) strains of JCV as the primary target for
SF2/ASF. This region encompasses several predicted binding sites
for DNA binding proteins including Pura, NF-1, MF3, Elk-1,
COE1, p300, and Zic3. At present, the importance of these
transcription regulators and their potential interplay with SF2/
ASF remains to be investigated.
SF2/ASF exhibits a modular structure consisting of two copies
of RNA binding motifs (RRM1 and RRM2), followed by an
arginine-serine rich (RS) domain [21]. Whereas the RRM
domains are responsible for RNA binding activity of ASF/SF2,
the RS region interacts with the core-splicing components [15],
[16]. Our results showed that the RRM1 domain has the capacity
to interact with the DNA sequence of JCV and that this
interaction is important for suppression of viral gene transcription.
Examination of SF2/ASF levels in several glial-derived cells
including human astrocytic tumor cells, U-87 MG, primary
human fetal astrocytes (PHFA) and primary human adult
astrocytes (PHAA) showed higher levels of SF2/ASF expression
in U-87 MG and PHAA where virus replicates poorly in
comparison to PHFA, routinely utilized for virus propagation.
Our results demonstrated that a decrease in the level of SF2/ASF
in both PHFA and PHAA increases the level of viral replication.
Altogether, results from the studies presented here identified a
novel regulatory pathway involving splicing factor SF2/ASF in
suppression of JCV gene transcription. This is a first report on the
ability of SF2/ASF to control viral gene expression at the
transcriptional level and suggests the operation of a novel
regulatory event that controls reactivation of JCV in non-glial as
well as glial cells.
Materials and Methods
Plasmid Constructs
pCGT7-SF2/ASF-FL expression plasmid, kindly provided by
Javier F. Caceres (Medical Research Council Human Genetics
Unit, Western General Hospital, Edinburgh EH4 2XU, Scotland,
United Kingdom) and was described previously [22]. pCGT7-SF2/
ASF-antisense expression plasmid was created with the following
primers: SF2 -F: 59-ACCTTCCAGGATCCATGTCGGGAGG-
TGGTGTGATT-3 and SF2-R: 59-ACCTTCCATCTAGAT-
TATGTACGAGAGCGAGATCT-39, and was cloned into the
pCGT7 vector in reverse orientation at XbaI/BamH1 sites. SF2/
ASFdomainmutationswerecreated byusing the followingprimers:
SF2-Mut.RS (1–196)-forward 59-ACCTTCCATCTAGATCGG-
GAGGTGGTG TGATTCGT-39, SF2-Mut.RS (1–196)-reverse:
59-ACCTTCCAGGATCCTTACCCATCA ACTTTAACCCG-
G-39; SF2-RRM1 (1–100)-forward: 59-ACCTTCCATCTAGAT-
CGGGAG GTGGTGTGATTCGT-39, SF2-RRM1 (1–100)-
reverse: 59-ACCTTCCAGGATCCTTA GCCGCCGCCTCG-
GCCTGT -39. SF2-Mut.RRM1 (101–248)-forward: 59-ACCTT-
CCATCTAGAGGCGGGGGTG GAGGTGGCGGA-39, SF2-
Mut.RRM1-(101–248) - reverse: 59-ACCTTCCAGGATCCTTA
TGTACGAGAGCGAGATCTGCT-39. pcDNA 3.1 (+) JCV-
Early expression plasmid was described earlier [23]. pBluescript-
JCV-Early construct was created as follows. JCV early genome was
amplified by using the following primers: Mad-1F (248–225), 59-
CTGGCTCGCAAAACATGTTCCCTT– 39; Mad-1R (2575-
2601), 59-TATAACCAGCTTTACTTAACAGTTGCA-39.T h e
amplification construct was cloned into pBlue-Script KS plasmid.
Cell cultures
Human malignant glioma cell line, U-87 MG, was obtained
from American Type Culture Collection (ATCC), and was grown
in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10%
heat-inactivated fetal bovine serum (FBS) and penicillin/strepto-
and 5th days post-transfection and processed by Western blotting using specific antibodies against T-Ag, SF2/ASF, and T7-SF2/ASF. Grb2 was probed
as a loading control after stripping of the same primary membranes used for Large T antigen and T7-tagged SF2/ASF protein detections. F. SF2/ASF
shows no inhibitory effect on SV40 Large T antigen expression in SVG-A cells. SVG A cells were plated in 6-well plates and transfected either with SF2/
ASF-sense or with SF2/ASF-antisense expression plasmids. T-Ag expression was detected by Western blotting. Expression of SF2/ASF and Grb2 was
detected in the same blots by using SF2/ASF-specific, T7-specific and Grb2-specific antibodies.
doi:10.1371/journal.pone.0014630.g002
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as previously described [24]. BSB8 cells were derived from
cerebellar medulloblastomas that developed in transgenic mice
expressing the early genome of the JCV [25]. SVG-A is a human
glial cell line which was established by transformation of primary
human fetal glial cells with an origin-defective SV40 virus [26]. All
cell lines and cultures were maintained at 37uC in a humidified
atmosphere with 7% CO2.
Figure 3. SF2/ASF inhibits JCV-early (JCVE) and –late (JCVL) transcription in PHFA cells. A. JCVE (black bars) or JCVL (grey bars) reporter
plasmids were transiently transfected into PHFA cells either alone or in combination with an SF2/ASF expression plasmid. B. SF2/ASF-mediated
inhibition of JCV-early transcription can be rescued by a specific siRNA against SF2/ASF. JCVE reporter plasmid was transiently transfected into PHFA
cells either alone or in combination with an SF2/ASF expression plasmid (lanes 2-6). At 12 h post-transfection, cells were transfected either with a
non-targeting siRNA or with a siRNA specific to SF2/ASF. C. Western blot analyses of the same extracts used for reporter assays in panel B, using
specific antibodies to T7-SF2/ASF and Grab2. D. Band intensities of SF2/ASF expression from panel E were quantified and showed as bar graph. The
Student’s t-test was performed to calculate ‘‘P’’ values in panels A, B, and D.
doi:10.1371/journal.pone.0014630.g003
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PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e14630Figure 4. SF2/ASF directly targets JCV regulatory region in vivo and in vitro. A. BSB8 cells were transfected with an T7-SF2/ASF expression
vector, cross-linked and ChiP assay performed using antibodies to Large T antigen (lane 4), Normal mouse serum (lane 5), T7 tagged SF2/ASF (lane 6),
and no antibody (lane 3). In lane 2, JCV Mad-1 genomic DNA was used as positive control. B. Gel shift analysis of JCV oligonucleotides spanning the
98-bp repeated region of the viral promoter with recombinant SF2/ASF. Four oligonucleotide probes (CR1, CR2, CR3, CR4), and JCV regulatory region
with early and late orientation are schematized at the top of the panel. C. Antibody supershift gel electrophoresis. CR3 oligonucleotide and GST-SF2/
ASF complexes were incubated with normal rabbit serum (NRS) or anti-GST antibodies for an additional 20 min prior to gel electrophoresis. The star
depicts a nonspecific band and the arrowhead points shifted specific complexes and the arrow points antibody supershifted specific complexes. D.
Coomassie blue staining of GST (lane 1) and GST-SF2/ASF (lane 2).
doi:10.1371/journal.pone.0014630.g004
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Transfection/infection of cells with the full-length JCV Mad-1
genome was described previously [27], [28]. Briefly, PHFA cells,
at a confluence of 1610
6 cells per T75-cm tissue culture flask, were
co-transfected/infected with the full-length JCV DNA (10 mg/
flask) in the presence or absence of pCGT7 plasmid expressing
SF2/ASF in the sense or antisense orientation using Fugene6
transfection as indicated by the manufacturer (Roche). The total
amount of DNA in each transfection mixture was kept constant
(14 mg) by the addition of empty pCGT7 vector. At 8 days post-
infection, cells were trypsinized and split into two equal portions.
One half was used for preparation of whole cell protein extract for
Western blot analysis, and the other half was split into two equal
volumes for DNA and RNA preparation using Qiaprep Spin
Miniprep kit (Qiagen), and RNeasy Mini kit (Qiagen), respectively.
DpnI assay and detection of replicated-viral DNA by
Southern blotting
Low molecular weight DNA purified from JCV-infected cells
was digested with Dpn I and BamH1 enzymes. Digested-DNA
samples were separated on 1% agarose gel and were transferred to
a nylon membrane. Replicated viral DNA was visualized upon
Figure 5. Characterization of the interaction between SF2/ASF and JCV regulatory region by gel shift assays. A. Competition analyses
of the CR3 oligonucleotide of JCV regulatory region. Nuclear extracts from PHFA cells incubated with end-labeled double stranded CR3
oligonucleotide probe in the presence of cold CR3 (lanes 3 and 4) and CR2 (lanes 5 and 6) oligonucleotides. B. Presence of RNA in nuclear extracts
influences the binding pattern to CR3 oligonucleotide. Nuclear extracts from PHFA cells incubated with end-labeled double stranded CR3
oligonucleotide probe in the presence or absence of RNase A (lanes 2 and 3, respectively). C. Gel shift analysis of JCV CR3 oligonucleotide in the
primary human fetal glial cell extracts. End-labeled (lanes 2 and 4) or cold (lane 3) CR3 oligonucleotide incubated with PHFA nuclear extracts.
Radioactively-labeled CR3/NP complexes (lanes 2 and 4) were used as reference to label and to cut the gel pieces containing the CR3/NP complexes
in cold oligonucleotide reaction (lane 3, GP2) and in nuclear extract control lane (lane 5, GP1). Dotted-lines indicate the vertical and horizontal lining
of expected running pattern of CR3/NP complexes. Solid boxes indicate the gel pieces (GP1, GP2), that were cut from the native gel. D. Nucleoprotein
complexes in native gel pieces (GP1 and GP2) from panel C were denatured, resolved by SDS-PAGE, and were analyzed by Western blotting, using a
specific anti-SF2/ASF antibody. In lane 1, nuclear extract from PHFA cells was loaded as positive control.
doi:10.1371/journal.pone.0014630.g005
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32P]-labeled JCV DNA probe
as described earlier [28].
RT-PCR
Total cellular RNA was extracted from JCV-infected PHFA cells
by using the Qiagen RNeasy kit according to the manufacturer’s
recommendations. After treatment with DNase I, followed by
phenol/chloroform extraction and ethanol precipitation, cDNAs
were synthesized using M-MuLV reverse transcriptase. RNA
templates were removed by RNase H digestion. A total of 100 ng
cDNA was used as template for PCR reactions. Viral transcripts
from JCV infected cells were determined by using following primers
in RT-PCR reactions. VP1-forward: 59-CTCATGTGGGAG-
GCTGTGAC-39, VP1-reverse: 59- TCCTCCTGTTAGTGTCC-
CAA-3, Large T-forward: 59-ATGGACAAAGTG CTGAATAG-
G-39, Large T-reverse: 59-TAGTGGTATACACAGCAAAAG-39
andGAPDH-Forward:59- TTCTCCCCATTCCGTCTTCC -39,
GAPDH-reverse: 59-GTACATGGTATT CACCACCC-39.T o
analyze the effect of SF2/ASF on JCV early gene expression,
PHFA and BSB8cellswere transfectedwith pCGT7-controlorwith
pCGT7-SF2/ASF expression plasmids. At 48 h of post-transfec-
tion, cells were harvested, and total RNA was extracted with an
RNA extraction kit (RNeasy, Qiagen) according to the manufac-
turer’s instructions. One microgram of RNA was then reverse-
transcribed using M-MuLV-reverse transcriptase and oligo-dT
primers. JCV Mad-1 genomic DNA and U87 MG cells were used
as positive and negative controls of amplifications, respectively. RT-
PCR reactions of the JCV-early region splicing were performed by
using following primers: PF (Mad-1 4801-4780): 59- CCTGA-
TTTTGGTACATGGAA -39 and PR (Mad-1 4291- 4313): 59-G-
TGGGGTAGAGTGTTGGGATCCT -39. Amplified gene prod-
ucts were resolved on a 3% DNA-agarose gel.
Detection of viral particles in culture medium by Q-PCR
Transfection/infection of cells with the full-length JCV-Mad1
genome was performed as described above. The culture medium
Figure 6. ‘‘RRM1’’ domain of SF2/ASF is required for the inhibition of JCV-Early promoter. A. Schematic representation of SF2/ASF-FL (1)
and its functional domain mutations, Mut.RS (2), RRM1-alone (3), and Mut.RRM1 (4). B. Expression of T7-SF2/ASF-FL and truncated forms of SF2/ASF
were detected by using anti-T7 (top panel) and anti-SF2/ASF (bottom panel) antibodies. C. BSB8 cells transfected with T7-SF2/ASF constructs,
schematized in panel A, cross-linked and ChiP assay performed using antibodies to actin (lane 4), to T-Ag (lane 5), to T7 (lanes 6 to 9), and no antibody
(lane 3). D. JCVE reporter plasmid transiently transfected into PHFA cells either alone (lane 1) or in combination with T7-SF2/ASF-FL-antisense (lane 2),
T7-SF2/ASF-FL-sense (lane 3), T7-SF2/ASF-Mut.RS (lane 4), T7-SF2/ASF-RRM1 (lane 5), and T7-SF2/ASF-Mut.RRM1 (lane 6) expression plasmids. E.
Subcellular localization of SF2/ASF and its truncated forms in PHFA cells.
doi:10.1371/journal.pone.0014630.g006
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PLoS ONE | www.plosone.org 9 January 2011 | Volume 6 | Issue 1 | e14630Figure 7. Downregulation of SF2/ASF induces JCV propagation in primary human fetal and adult astrocytes. A. Western blot analyses
of SF2/ASF expression in PHFA and PHAA cells. Grb2 was probed as a loading control. Band intensities were quantified and shown as a bar graph. B.
PHFA and PHAA cells infected with a lentivirus encoding SF2/ASF-shRNAs at day 0, transfected/infected with JCV Mad-1 strain at day 1. Q-PCR
analyses of JCV viral particles in culture supernatants were performed as described in Fig. 1C. C. Whole cells extracts were prepared from the same
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and after centrifugation at 10,000 rpm for 10 minutes to remove
cell debris, supernatants were collected and incubated at 95uC for
10 minutes to inactivate virus. Ten microliters of the medium was
then used as a template in Q-PCR reactions. The standard curve
was obtained after serial dilution of pJCV, a plasmid containing
the whole genome of the JCV Mad-1 strain, knowing that 10 ng of
pJCV correspond to 109 copies of viral genome. The standard
curve was then used to extrapolate the viral load of each sample.
Negative and positive controls were included in each reaction and
each sample was tested in triplicate. All Q-PCR analyses were done
by using Lightcycler 480 (Roche). Primers were JCV Q-PCR-
forward: 59-AGTTGATGGGCAGCCTATGTA-39 and JCV Q-
PCR-reverse: 59- TCATGTCTGGGTCCCCTGGA-39. The
probe for the Q-PCR was 59-/5HEX/CATGGA TGCTCAAG-
TAGAGGAGGTTAGAGTTT/3BHQ_1/-39.
Reporter gene assays
Reporter gene constructs containing the regulatory region of the
JCV Mad-1 strain was described previously [23]. Briefly, Mad-1
(4989 to 480) region was PCR-amplified and inserted into the
BamHI site of the pBLCAT3 vector in early and late orientations.
The resulting plasmids were called pBLCAT3-Mad1-Early and
pBLCAT3-Mad1-Late. pBLCAT3-BKV-Early and pBLCAT3-
BKV-Late plasmids were described previously [29]. PHFA cells
were transfected with these constructs in the presence or absence
of expression plasmids for SF2/ASF-FL and its mutant forms. At
48h post-transfection, cells were extracted with a series of freeze/
thaw cycles, and the CAT activity of the samples was determined.
Immunocytochemistry
In order to show localization of SF2/ASF in glial cells, PHFA
cells were seeded in two-well chamber slides and transfected with
pCGT7-SF2-FL, pCGT7-SF2-Mut.RS, pCGT7-SF2-Mut.RRM1,
and pCGT7-SF2-RRM1 plasmids. After 48 h, cells were fixed with
cold acetone/methanol (1/1) for 2 minutes and washed three times
with PBS. Cells were treated with a 5% BSA solution, followed by
incubation with T7 monoclonal antibody. Cells were then
incubated with FITC-conjugated secondary antibody, mounted
with aqueous mounting medium, and examined under immuno-
flourescence microscope. To analyze infection of PHAA and PHFA
with JCV, cells were plated in 2 well chamber slides at 10 day post-
infection and fixed with cold acetone/methanol (1/1). After
treatment with a 5% BSA solution, samples were incubated with
JCVVP1-specificmonoclonalantibodyfollowedbyincubationwith
FITC-conjugated secondary antibody. Samples were mounted with
aqueous mounting with DAPI, and examined for microscopic
immunoflourescence.
Production and purification of GST proteins
SF2/ASF was amplified with the following primers, GST-SF2-
Forward: 59-ACCTTCCAGGATCCATGTCGGGAGGTG GT-
GTGATT-39, GST-SF2-Reverse: 59-ACCTTCCAGAATTCTT-
ATGTACGAGAG CGAGATCT -39,a n dc l o n e di n t oB a m H Ia n d
EcoRI sites of the pGEX2T E-coli expression vector. Bacterial
cultures were incubated in one liter LB growth medium at 37uCu n t i l
they reached a conflucence of 0.6 at 595.0 nm wavelength (wl) after
which they were transferred to 28uC and treated with IPTG (5 mg/
ml). Cultures were centrifuged at 5 k rpm for 10 min and re-
suspended in 20 ml of PENT buffer (20 mM tris-HCL pH 8.0,
100 mM NaCl, 1 mM EDTA, 0.5% NP-40 1% N-L-sarcosyl, and
general protease inhibitors), after which they were lyzed by
sonication. Bacterial lysates were centrifuged at 15 k rpm for 15
minutes. Clear lysates were incubated with 150 mlo fg l u t a t h i o n e
sepharose beads overnight, centrifuged at 3 k rpm for 5 minutes, and
resuspended in TNN buffer (150 mM NaCl, 40 mM Tris pH 7.4,
1% NP-40 (ipegal), 1 mM DTT, 1 mM EDTA). Beads were washed
in TNN buffer three times, and resuspended in PBS. The integrity of
the proteins was tested by SDS-PAGE. SF2/ASF-FL protein was
cleaved from the GST fusion protein by thrombin, and was
subsequently used in gel shift experiments.
Chromatin immunoprecipitation, (ChIP) assay
BSB8 cells were transiently transfected with pCGT7-SF2/ASF
full length and its truncated forms. ChIP assays were performed as
described previously [30]. Briefly, proteins were cross-linked to
DNA by formaldehyde, following by sonication to fragment the
chromatin and immunoprecipitation of specific proteins to obtain
DNA segments. Cross-linking was reversed and DNA was
analyzed by PCR.
RNA interference
To knock-down expression of SF2/ASF, PHFA cells were seeded
(5610
5 cells per well) in 60 mm dishes. After 24 h, cells were
transfected with 200 pmol short interfering RNA (siRNA) per well
(Santa Cruz), using Oligofectamine (Invitrogen). After 72 h, total
proteins were prepared. Lentivirus-based U6-promoted SF2
shRNA constructs were generated by cloning PCR products
carrying sense and antisense oligonucleotides of SF2/ASF into the
pLL3.7 vector as described previously [31]. Two SF2 shRNA
constructs were made to target the nucleotide sequences 35–55
(shA), and 423-443 (shB) of the human SF2 cDNA (GenBank
accession number AAH33785.1). The viruses were packaged in
293T (human embryonic kidney) cells according to the procedure
described previously [32]. Primary human fetal and adult astrocytes
wereplated insix-well platesat 50% confluencyand were incubated
with1 mloftheviralsupernatants.Theinfected cellswerethen kept
in regular complete medium for 48 h. Inspection with fluorescence
microscopy confirmed the presence of more than 80% of GFP-
positive cells after viral infection. The level of SF2 in infected cells
was evaluated by Western blot analysis.
Immunohisthochemistry
Immunohisthochemistry was performed using the Avidin-
Biotin-Peroxidase method according to manufacturer’s suggestions
(Vector Laboratories). Control and PML brain sections were
blocked with 5% normal horse serum in 0.1% PBS/BSA for 2 h at
room temperature. SF2/ASF antibody (Clone 96, 1:500 dilution,
Invitrogen) was incubated overnight at room temperature.
Biotinylated secondary anti-mouse was incubated for 1 h at room
temperature (1:250 dilution). Sections were incubated with avidin-
biotin (Vector Laboratories) for 1 h at room temperature, rinsed
with PBS, and developed with deaminobenzidine (Sigma). Finally,
the sections were mounted with Permount (Fisher Scientific).
infections as described in panel B and processed for Western blotting by using specific antibodies against SF2/ASF and VP1. Grb2 was probed as
loading control. D. Immunocytochemical analyses of VP1 expression in PHFA and PHAA cells infected with JCV. E. Quantification of VP1 expression in
infected cells from panel D.
doi:10.1371/journal.pone.0014630.g007
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The following oligonucleotides were used in band shift assays:
kB: 59-AAAACAAGGGAATTTCCCTGGCCTC-39. ORI: 59-
GGAGGCGGAGGCGGCCTCGGCC TCC -39. CR1: 59-CC-
TGTATATATAAAAAAAAGGGAAG-39. CR2: 59-GGATAG-
CTGCCA GC CAACGATGAGC-39. CR3: 59-TCATACC-
TAGGGAGCCAACCAGCTA-39. CR4: 59-AC AGCCAGTA-
AACAAAGCACAAGGC-39. Band shift assays were carried out
as described previously [33], [34]. Recombinant SF2 or nuclear
extracts from PHFA were incubated with [
32P]-end labeled
oligonucleotides (50,000 cpm/reaction) in a binding buffer
containing 1.0 mg poly (dI–dC), 12 mM HEPES (pH 7.9), 4 mM
Trish [pH 7.5], 60 mM KCl, 5 mM MgCl2 and 1.0 mM DTT.
The reaction mixture was incubated at 4uC for 1 h to allow
assembly of DNA–protein complexes. The complexes were then
resolved on a 6% polyacrylamide gel in 0.56 TBE (16 TBE is
89 mM Tris– HCl [pH 8.0], 89 mM boric acid and 2 mM EDTA
[pH 8.0]). The gels were dried, and complexes were detected by
autoradiography. The presence of SF2/ASF in the CR3/
nucleoprotein (CR3/NP) was analyzed by gel shift followed by
Western blot analysis. End-labeled or unlabeled CR3 oligonucle-
otide was incubated with nuclear extracts from PHFA cells and
complexes were resolved on 6% native PAGE. End-labeled CR3/
NP complexes were used as reference to unlabeled-CR3/NP
complexes, and the DNA/protein complexes were cut from the
gels and elution of its contents were analyzed by SDS-PAGE
followed by Western blot analysis using anti-SF2/ASF antibody.
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay for cell proliferation
PHFA and PHAA cells were plated in 6-well plates (2610
5), and
infected either with Lenti-control or Lenti-SF2/ASF-shRNA.
Seventy two hours postinfection, cells were washed with PBS, and
incubated with 1 ml of MTT working solution (DMEM with
0.5 mg/ml MTT) for 1 hour at 37uC. At the end of the incubatuion,
the converted dye was solubilized with 1 ml acidic isopropanol
(0.004 M HCL in isopropanol). Suspension was pipetted up and
down to make sure that the converted dye dissolved. The dye solution
was transferred into 1.5 ml eppendorf tubes, and centrifuged at
15,000 rpm for 5 min. The supernatant was transferred into new
eppendorf tube. Absorbance of the converted dye was measured at a
wavelength of 570 nm with background subtraction at 650 nm.
Supporting Information
Figure S1 Effect of SF2/ASF on transcriptional activity of BKV
and E2F promoter sequences. PHFA cells were cotransfected with
either pCGT7-empty plasmid or pCGT7-SF2/ASF and pBLCAT3-
early, pBLCAT3-late, and pBLCAT3-E2F reporter plasmids. CAT
enzyme activities were analyzed at 48 hours posttransfection.
Found at: doi:10.1371/journal.pone.0014630.s001 (1.31 MB EPS)
Figure S2 SF2/ASF expression in normal and PML brain.
Immunohistochemistry for the SF2/ASF was performed as
described in materials and methods. Expression of SF2/ASF was
detected in the nuclei of the cells in the normal (top panel) and
PML (bottom panel) brain sections. A noticeable downregulation
of SF2/ASF expression was observed in PML brain sections.
Found at: doi:10.1371/journal.pone.0014630.s002 (5.89 MB EPS)
Figure S3 JCV replication in glial and non-glial cells. Primary
human fetal astrocytes (PHFA), peripheral blood mononuclear
cells (PBMC), human glioblastoma cell line (U87 MG), human
ovarian cancer cell line (HeLa), and human B-cell lymphoma cell
line (WIL2N) were infected with either Lenti-control or Lenti-
SF2/ASF.shRNA. At 48 hours postinfections, the cells were
infected with JCV Mad1 strain (30 MOI/cell). JCV genomic
DNA was analyzed in growth medium by Q-PCR at 14 days
postinfection.
Found at: doi:10.1371/journal.pone.0014630.s003 (1.34 MB EPS)
Figure S4 Effect of Lenti-control and Lenti-SF2/ASF-shRNA
on the growth of PHFA and PHAA cells. A. PHFA and PHAA
cells were plated in 6-well dishes, either infected with Lenti-control
and Lenti-SF2/ASF-shRNA or left uninfected. At 72 hours
postinfection, an MTT assay was performed to analyze cell
viability as described in the "Materials and Methods" section. B.
Western blot analyses of SF2/ASF expression in PHFA and
PHAA cells infected with Lenti-control and Lenti-SF2/ASF-
shRNA at 72 hours postinfection. Grb2 was probed in the same
blots as the loading control.
Found at: doi:10.1371/journal.pone.0014630.s004 (1.41 MB EPS)
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